Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Lithium
3. Lithium has shown to reduce risk of suicide
4. Lithium characterization
5. Lithium disadvantages
6. Lithium response
7. Lithium response - brain imaging
8. Lithium response -imaging ubnormalities
9. Lithium response - mood disorders
10. Factors influencing lithium response
11. Clinical predictors of lithium prophylactic efficacy
12. Definition of response
13. Definition of response - not complete responders
14. Response as a continuous variable
15. Definition of response - number of episodes
16. The role of genetics
17. Evidences for genetic influence on lithium efficacy
18. Genetic influence on lithium response - studies
19. The mode of inheritance is hard to be established
20. Heterogeneity may explain discrepancies
21. Difficulties in identifying a pattern of transmission
22. No certain susceptibility gene for lithium efficacy
23. Lithium induces a number of effects at:
24. Lithium: possible mechanism of action (1)
25. Lithium - the things it does
26. Lithium: possible mechanism of action (2)
27. Lithium effect on cytoskeletal function
28. Lithium inhibits the recycling of inositol substrates
29. Serotonin involvement in lithium efficacy
30. Lithium increased the levels of 5-HIAA
31. Serotonin pathway
32. Lithium increased the levels of transporter proteins
33. The turnover of 5-HT is due to lithium treatment
34. Dopamine pathway
35. Lithium and GSK-beta3
36. Lithium induced G-protein phosphorylation
37. Lithium influences gene expression
38. Mechanism of action of psychotrophic drugs
39. Lithium and gene expression
40. Lithium mechanism of action
41. Pharmacogenetic studies (1)
42. Pharmacogenetic studies (2)
43. Definition of response in our studies
44. Response index
45. Inositol polyphasphate 1-phosphatase (INPP1)
46. Gamma-1 isoenzyme of phospholipase C (PLCG1)
47. PLCG1: conflicting results
48. Tryptophan hydroxylase gene
49. Methods
50. Results (1)
51. TPH variants/frequency of episodes vs. treatment
52. Result (2)
53. Result (3)
54. Serotonin transporter gene
55. 5-HTTLPR variants and EF vs. lithium treatment (1)
56. 5-HTTLPR variants and EF vs. lithium treatment (2)
57. Serotonin transporter gene and lithium prophylaxis
58. Descriptive data of the sample (1)
59. Descriptive data of the sample (2)
60. Conclusions
61. Lithium salts long-term response in bipolar illness
62. GSK 3 beta is a key factor in signal transduction
63. Results (4)
64. Results (5)
65. Mitochondrial DNA
66. Pharmacogenetic studies
67. Differences among pharmacogenetic studies
68. Conclusions (1)
69. Conclusions (2)
70. Hopes (1)
71. Hopes (2)

Topics Covered

• Lithium treatment in the long-term maintenance of mood disorders
• The issue of evaluating lithium response
• Role of genetic factors
• Mechanism of action of lithium candidate genes in lithium response
• Inositol polyphosphate 1- phosphatase (INNP1)
• Gamma-1 isoenzyme of phospholipase C (PLCG1)
• Tryptophan hydroxylase gene (TPH
• A218C)
• Serotonin transporter gene (5-HTTLPR)
• Glycogen synthase kinase 3-beta (GSK3B-50 T/C)

Links

Series:

• Psychopharmacogenetics

Categories:

• Genetics & Epigenetics
• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Neurology

Talk Citation

Serretti, A. (2007, October 1). Genetic polymorphisms influencing response to lithium [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/IHJA9647.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Prof. Alessandro Serretti has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.